Position of the Transparency Council – Vistogard (uridine triacetate)
At its meeting on 26 May 2025, the Transparency Council adopted position No. 65/2025 on the validity of granting approval for reimbursement of the drug Vistogard (uridine triacetate) for the indication of uridine-responsive epileptic and developmental encephalopathy